Free Trial

Molecular Templates (MTEM) Competitors

Molecular Templates logo

MTEM vs. AMGN, GILD, VRTX, REGN, ALNY, BIIB, UTHR, INCY, EXEL, and NBIX

Should you be buying Molecular Templates stock or one of its competitors? The main competitors of Molecular Templates include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Exelixis (EXEL), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry.

Molecular Templates vs.

Molecular Templates (NASDAQ:MTEM) and Amgen (NASDAQ:AMGN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk, community ranking and dividends.

In the previous week, Amgen had 48 more articles in the media than Molecular Templates. MarketBeat recorded 48 mentions for Amgen and 0 mentions for Molecular Templates. Amgen's average media sentiment score of 1.20 beat Molecular Templates' score of 0.00 indicating that Amgen is being referred to more favorably in the news media.

Company Overall Sentiment
Molecular Templates Neutral
Amgen Positive

Amgen has a consensus target price of $309.22, indicating a potential upside of 13.72%. Given Amgen's stronger consensus rating and higher possible upside, analysts clearly believe Amgen is more favorable than Molecular Templates.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Molecular Templates
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Amgen
2 Sell rating(s)
12 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.38

Amgen received 1217 more outperform votes than Molecular Templates when rated by MarketBeat users. Likewise, 71.71% of users gave Amgen an outperform vote while only 67.32% of users gave Molecular Templates an outperform vote.

CompanyUnderperformOutperform
Molecular TemplatesOutperform Votes
342
67.32%
Underperform Votes
166
32.68%
AmgenOutperform Votes
1559
71.71%
Underperform Votes
615
28.29%

Amgen has higher revenue and earnings than Molecular Templates. Molecular Templates is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Templates$23.48M0.00-$8.12M-$2.70N/A
Amgen$34.13B4.28$4.09B$10.9624.81

95.5% of Molecular Templates shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 13.9% of Molecular Templates shares are held by insiders. Comparatively, 0.8% of Amgen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Amgen has a net margin of 12.24% compared to Molecular Templates' net margin of -61.35%. Amgen's return on equity of 176.32% beat Molecular Templates' return on equity.

Company Net Margins Return on Equity Return on Assets
Molecular Templates-61.35% -260.50% -46.90%
Amgen 12.24%176.32%11.71%

Molecular Templates has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Amgen has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.

Summary

Amgen beats Molecular Templates on 15 of the 18 factors compared between the two stocks.

Get Molecular Templates News Delivered to You Automatically

Sign up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MTEM vs. The Competition

MetricMolecular TemplatesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1,000.00$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.10%
P/E Ratio0.009.0626.7719.70
Price / SalesN/A259.83393.27122.35
Price / CashN/A65.8538.2534.62
Price / BookN/A6.456.774.50
Net Income-$8.12M$143.98M$3.23B$248.22M

Molecular Templates Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MTEM
Molecular Templates
N/AN/AN/AN/A$1,000.00$23.48M0.00260
AMGN
Amgen
4.3708 of 5 stars
$275.85
+1.3%
$310.18
+12.4%
-12.1%$148.33B$34.13B36.5425,200Positive News
Analyst Forecast
GILD
Gilead Sciences
4.6504 of 5 stars
$106.16
+3.6%
$110.55
+4.1%
+57.4%$132.06B$28.74B286.9217,000Positive News
Analyst Forecast
Options Volume
VRTX
Vertex Pharmaceuticals
4.6184 of 5 stars
$440.66
+0.5%
$515.04
+16.9%
-3.0%$112.64B$11.10B-200.304,800Positive News
REGN
Regeneron Pharmaceuticals
4.7898 of 5 stars
$596.54
+0.4%
$890.60
+49.3%
-39.3%$64.41B$14.09B15.5811,900Dividend Announcement
Ex-Dividend
ALNY
Alnylam Pharmaceuticals
4.1825 of 5 stars
$291.86
+2.3%
$319.17
+9.4%
+91.5%$38.06B$2.35B-134.502,000Positive News
BIIB
Biogen
4.8956 of 5 stars
$129.44
+3.1%
$191.30
+47.8%
-43.9%$18.97B$9.82B11.578,720Positive News
UTHR
United Therapeutics
4.9794 of 5 stars
$305.31
0.0%
$392.00
+28.4%
+11.7%$13.77B$2.99B13.41980Positive News
Analyst Revision
INCY
Incyte
4.8759 of 5 stars
$63.81
+0.8%
$73.53
+15.2%
+10.8%$12.35B$4.41B236.342,320Positive News
EXEL
Exelixis
4.0985 of 5 stars
$44.69
-1.6%
$38.94
-12.9%
+104.1%$12.19B$2.30B25.251,220Positive News
Insider Trade
NBIX
Neurocrine Biosciences
4.8934 of 5 stars
$122.82
+1.5%
$162.00
+31.9%
-14.6%$12.16B$2.41B37.331,200Positive News

Related Companies and Tools


This page (NASDAQ:MTEM) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners